$3.36
arrow_drop_down2.60%Key Stats | |
---|---|
Open | $3.41 |
Prev. Close | $3.45 |
EPS | -0.34 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $214.65M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 3.31 | 3.43 |
52 Week Range | 2.86 | 13.70 |
Ratios | |
---|---|
EPS | -0.34 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab